The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b

Basit Öğe Kaydı
dc.contributor.authorMutlu, Hasan
dc.contributor.authorGündüz, Şeyda
dc.contributor.authorBüyükçelik, Abdullah
dc.contributor.authorYıldız, Özcan
dc.contributor.authorUysal, Mükremin
dc.contributor.authorTural, Deniz
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorÇoşkun, Hasan Şenol
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:17Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:17Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000345547700009
dc.descriptionPubMed ID: 25022784
dc.description.abstractThe effects of cytoreductive nephrectomy (CRN) on prognosis of patients with metastatic renal cell cancer (RCC) using antiangiogenic targeted agents were evaluated. The median overall survival was significantly higher in the group that received CRN (P = .034). We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. Background: Targeted therapy has improved the survival of patients with metastatic RCC. In the present study, we evaluated whether there was an effect of cytoreductive surgery on prognosis of patients with metastatic RCC using antiangiogenic tyrosine kinase inhibitor (TKI) agents. Patients and Methods: A total of 52 patients with metastatic RCC from Akdeniz University, Afyon Kocatepe University, and Medipol University participated in the study. All the patients had received targeted antiangiogenic therapy after interferon alfa-2b. According to previous CRN, the patients were divided into 2 groups as CRN (+) and CRN (-). Results: The CRN (+) group was younger than the CRN (-) group (P < .001) and the hemoglobin levels were significantly higher in the CRN (+) group (P = .023). The median progression-free survival time from the date of starting TKIs were 8.5 and 3.0 months for the CRN (+) and CRN (-) groups, respectively (P = .104). The median overall survival was 15.1 and 5.4 months for the CRN (+) and CRN (-) groups, respectively (P = .034). Conclusion: We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. However, the indications of CRN might be limited to good-risk patients with metastatic RCC. Further randomized studies are warranted to clarify the necessity of CRN in patients with metastatic RCC.
dc.identifier.citationMutlu, H., Gündüz, Ş., Büyükçelik, A., Yıldız, Ö., Uysal, M. Tural, D. ... Çoşkun, H. Ş. (2014). The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. Clinical Genitourinary Cancer, 12(6), 447-450. https://dx.doi.org/10.1016/j.clgc.2014.06.006
dc.identifier.doi10.1016/j.clgc.2014.06.006
dc.identifier.endpage450
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue6
dc.identifier.scopusqualityQ1
dc.identifier.startpage447
dc.identifier.urihttps://dx.doi.org/10.1016/j.clgc.2014.06.006
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2187
dc.identifier.volume12
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCIG Media Group
dc.relation.ispartofClinical Genitourinary Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAngiogenesis
dc.subjectNephrectomy
dc.subjectPrognosis
dc.subjectRenal Cell Cancer
dc.subjectSurvival
dc.titleThe necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Yildiz, Ozcan-2014.pdf
Boyut:
335.16 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu